In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crucell Falls Back on Vaccines

Executive Summary

Forced by a series of setbacks to downsize its antibody platform, Crucell is now turning to vaccine applications of its human cell production technology to satisfy its product developer ambitions.

You may also be interested in...



Shire Lays a Stake in Vaccines

Shire has been buffeted by management upheaval and generic and branded competition. But the group's foray into vaccines is a sensible long-term bet, offering it a low-risk route into R&D.

Long End of the Stick

Sustainable and increasingly focused, mid-sized vaccines companies are leading the way in European biotech, catalyzed by fears of bioterrorism and a re-emerging belief that prevention trumps cure, both practically and pharmaco-economically.

Crucell Cuts a Good Bargain

J&J Centocor's deal with Crucell demonstrates how large pharma companies are being forced to make bigger sacrifices in return for potential products. Centocor is believed to be paying just $2 million, with $1-2 million in annual fees but the deal value could reach $100 million and give J&J an opportunity to strengthen its oncology product line. And Crucell gets closer to its goal of being a product company without taking on all the risks of drug development.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV004713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel